Healthcare Industry News: cryoablation
News Release - March 15, 2007
Sanarus Medical Secures $15 Million Round of FinancingPLEASANTON, Calif., March 15 (HSMN NewsFeed) -- Sanarus Medical, a privately held company focused on developing and marketing minimally invasive devices for the diagnosis and treatment of breast tumors, announced today that it has closed a $15 million round of financing led by Easton Capital Partners and Mosaix Ventures, both leading venture capital investors in healthcare. Investing in the Series E round are current investors; U.S. Venture Partners, Forward Ventures, Alta Partners, Federated Kaufmann Fund, Pequot Ventures, Industry Ventures and CHANNEL Medical Partners. In conjunction with the financing, Sanarus announced the addition of John Friedman of Easton Capital Partners, to the Company's Board of Directors. "We are very pleased to have invested in a company whose revolutionary platform addresses so many critical patient and physician needs in the treatment and diagnosis of breast disease," said John Friedman, of Easton Capital Partners.
Sanarus is in the early commercialization of its Visica® Treatment System, for cryoablation of breast fibroadenomas. The Visica Treatment System offers women a minimally invasive, office based procedure to definitively treat benign breast tumors versus the traditional treatment of open surgical removal. Effective January 1, 2007, Sanarus obtained a new Category 1 CPT reimbursement code for the "cryosurgical ablation of fibroadenomas," making it possible for physicians to get paid for this innovative treatment.
Sanarus also markets the Cassi® Rotational Core Biopsy System, an automated hand held breast biopsy device which uses patented Stick FreezeTechnology® to secure large contiguous core biopsy samples. Sanarus also markets the ImarC Tissue Marker System, a line of breast tissue markers that are permanently visible under all imaging modalities.
About Sanarus Medical
Sanarus Medical, headquartered in Pleasanton, California, is dedicated to advancing women's health by providing minimally invasive products for the diagnosis and treatment of breast tumors. The Sanarus cryoablation technology enables a cost effective, office based procedure which provides an important alternative to women that currently have to undergo an operating room based, surgically intensive procedure. Privately held, Sanarus Medical is funded by leading healthcare venture capital investors. For more information, visit our website at www.sanarus.com.
Source: Sanarus Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.